Using Mesalamine to Treat Acute Liver Failure
Author Information
Author(s): Park Byeongmin, Kim Eun Hye, Jang Hochung, Kim Yelee, Ryu Youngri, Choi Jiwoong, Shin Dongwon, Lee Myung Chul, Yang Yoosoo, Kim Kwangmeyung, Lee Sangmin, Kim Sun Hwa, Shim Man Kyu
Primary Institution: Korea Institute of Science and Technology (KIST)
Hypothesis
Can mesalamine be repurposed for the treatment of drug-induced acute liver failure through supramolecular nanoassembly?
Conclusion
The study shows that supramolecular nanoassemblies of mesalamine can effectively target and treat acute liver failure in mouse models.
Supporting Evidence
- Mesalamine is modified to form nanoassemblies that target liver tissues.
- SPNs showed significant therapeutic efficacy in mouse models of acute liver failure.
- SPNs minimize side effects by releasing mesalamine specifically in injured cells.
Takeaway
Researchers found a new way to use an existing medicine called mesalamine to help treat a serious liver problem caused by drugs.
Methodology
The study involved creating a mesalamine prodrug that forms nanoassemblies, which were tested in mouse models of acute liver failure.
Limitations
The study primarily used mouse models, which may not fully replicate human responses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website